Jie Xiang

TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.

TL;DR: It is found that among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without and a greater number ofComorbidities also correlated with poorer clinical outcome.

TL;DR: The 2019-nCoV epidemic spreads rapidly by human-to-human transmission and the disease severity (including oxygen saturation, respiratory rate, blood leukocyte/lymphocyte count and chest X-ray/CT manifestations) predict poor clinical outcomes.

TL;DR: Comorbidities are present in around one fourth of patients with COVID-19 in China, and predispose to poorer clinical outcomes, and have significantly escalated risks of reaching to the composite endpoint compared with those who had a single comorbidity.

TL;DR: Patients with COPD who developed COVID-19 showed a higher risk of admission to the intensive care unit, mechanical ventilation, or death and a significantly higher proportion of increased activated partial thromboplastin time.